Anti‐IL‐5 therapies for chronic obstructive pulmonary disease

Review (6 studies, n=5542) found mepolizumab and benralizumab probably reduce the rate of moderate and severe exacerbations in the highly selected group of people who have both COPD and higher levels of blood eosinophils, highlighting importance of disease phenotyping in COPD.

Source:

Cochrane Database of Systematic Reviews